2,120 results match your criteria: "Sanofi-Genzyme R&D Center[Affiliation]"
Front Neurol
December 2024
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials.
J Neurol
January 2025
Biogen, Milan, Italy.
Objective: In Italy, around 137,000 people live with multiple sclerosis, facing organizational complexities due to the current model's limited focus on proximity care. This project aims to define a proximity model, in accordance with recent developments in the Italian healthcare landscape, engaging over 150 healthcare stakeholders and potentially impacting approximately 14,000 patients.
Methods: An analysis was pursued to map the multiple sclerosis pathway, followed by interviews to capture the actual implementation in Italian Multiple Sclerosis Centers.
Mult Scler
January 2025
Departamento de Neurología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Mult Scler
January 2025
Department of Neurology, St. Josef-Hospital, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum, Germany.
Background: In Europe, ofatumumab is approved for breastfeeding, but data on its transfer into breast milk and clinical experience are lacking.
Objective: To analyze (1) health, development, and adverse events after live vaccination of ofatumumab-exposed breastfed infants and (2) detectability of ofatumumab in breast milk, and to calculate the relative infant dose (RID) using two methods, the traditional method and a second method considering maternal exposure to multiple ofatumumab doses and extended collection period.
Methods: In this observational study, clinical data were collected by standardized telephone interviews up to 2 years postpartum.
Lancet Oncol
January 2025
Melanoma World Society, HERACLIN Institute for Data Management in Healthcare, Neuenhagen, Germany.
J Allergy Clin Immunol
January 2025
Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Background: Rhinoconjunctivitis phenotypes are conventionally described on the basis of symptom severity, duration and seasonality, and aeroallergen sensitization. It is not known whether these phenotypes fully reflect the patterns of symptoms seen at a population level.
Objective: We sought to identify phenotypes of rhinoconjunctivitis on the basis of symptom intensity and seasonality using an unbiased approach and to compare their characteristics.
Respir Res
December 2024
National Jewish Health, Denver, USA.
Background: We sought consensus among practising respiratory physicians on the prediction, identification and monitoring of progression in patients with fibrosing interstitial lung disease (ILD) using a modified Delphi process.
Methods: Following a literature review, statements on the prediction, identification and monitoring of progression of ILD were developed by a panel of physicians with specialist expertise. Practising respiratory physicians were sent a survey asking them to indicate their level of agreement with these statements on a binary scale or 7-point Likert scale (- 3 to 3), or to select answers from a list.
Hum Brain Mapp
January 2025
Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK.
Disruptions to brain networks, measured using structural (sMRI), diffusion (dMRI), or functional (fMRI) MRI, have been shown in people with multiple sclerosis (PwMS), highlighting the relevance of regions in the core of the connectome but yielding mixed results depending on the studied connectivity domain. Using a multilayer network approach, we integrated these three modalities to portray an enriched representation of the brain's core-periphery organization and explore its alterations in PwMS. In this retrospective cross-sectional study, we selected PwMS and healthy controls with complete multimodal brain MRI acquisitions from 13 European centers within the MAGNIMS network.
View Article and Find Full Text PDFNetw Neurosci
December 2024
Neuroradiology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system. Structures affected in MS include the corpus callosum, connecting the hemispheres. Studies have shown that in mammalian brains, structural connectivity is organized according to a conservation principle, an inverse relationship between intra- and interhemispheric connectivity.
View Article and Find Full Text PDFJ Neurol
December 2024
Department of Neurosciences Rita Levi Montalcini, University of Turin, Turin, Italy.
Introduction: Non-motor symptoms (NMS) in Parkinson's disease (PD) can fluctuate daily, impacting patient quality of life. The Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire, a recently validated tool, quantifies NMS fluctuations during ON- and OFF-medication states. Our study aimed to validate the Italian version of NoMoFA, comparing its results to the original validation and further exploring its clinimetric properties.
View Article and Find Full Text PDFJ Allergy Clin Immunol
December 2024
Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, University of Cincinnati, Cincinnati, Ohio.
Background: There is no global agreement on the definition of chronic spontaneous urticaria (CSU) remission.
Objective: Our aim was to generate a consensus for clinical definitions of CSU-related terms focused on remission.
Methods: The World Allergy Organization Urticaria Committee systematically reviewed current available longitudinal articles.
Mult Scler
January 2025
Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.
Background: The effect of cognitive reserve (CR) on cognition in people with relapsing-remitting multiple sclerosis (pwRRMS) has been partially investigated.
Objectives: We aimed to explore the long-term cognitive trajectories of pwRRMS based on their CR, measured using the Vocabulary Knowledge Test (VOC).
Methods: 78 pwRRMS underwent a neuropsychological evaluation at baseline and after a mean follow-up of 6.
Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.
View Article and Find Full Text PDFBrain Commun
November 2024
The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet Glostrup, 2600 Glostrup, Denmark.
Currently, there are limited therapeutic options for patients with non-active secondary progressive multiple sclerosis. Therefore, real-world studies have investigated differences between patients with relapsing-remitting multiple sclerosis, non-active secondary progressive multiple sclerosis and active secondary progressive multiple sclerosis. Here, we explore patterns and predictors of transitioning between these phenotypes.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy.
Background: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been validated in many cross-sectional studies. However, longitudinal data on BICAMS subset trajectories and their correlation with disease activity during follow-up are scarce.
Objectives: We aimed to (i) assess BICAMS changes in MS patients initiating high-efficacy disease-modifying-treatments (DMTs), (ii) compare these changes based on maintenance of "no-evidence-of-disease-activity" (NEDA-3) status over 24 months, and (iii) determine baseline clinical parameters predictive of cognitive changes.
Neurol Neuroimmunol Neuroinflamm
January 2025
Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.
Background And Objectives: In patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), acute disease activity is generally identified through medical history, neurologic examination, and imaging. However, these may be insufficient for detecting disease activity in specific conditions. This study aimed to investigate the dynamics of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) after clinical attacks and to assess their utility in discriminating attacks from remission in patients with MOGAD.
View Article and Find Full Text PDFNat Rev Dis Primers
December 2024
Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy. Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis requiring mechanical ventilation. GBS is usually a monophasic disease in which an aberrant immune response to an infection or other trigger damages the peripheral nerves.
View Article and Find Full Text PDFTransl Oncol
February 2025
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Electronic address:
Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. Our retrospective study assessed liquid biopsies and tumor tissue analyses for two potential biomarkers: danger-associated molecular pattern (DAMP) S100A8/A9 and its source, neutrophils.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
January 2025
Katholisches Klinikum Bochum, St. Josef Hospital, Bochum, Germany.
Background And Objectives: Ocrelizumab labeling advises contraception for women during treatment and for 6-12 months thereafter. Because pregnancies may occur during this time, it is critical to understand pregnancy and infant outcomes in women with multiple sclerosis (MS) after ocrelizumab exposure.
Methods: Pregnancy cases reported to Roche global pharmacovigilance until 12 July 2023 were analyzed.
Cells
December 2024
Departments of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Solid tumors vary by the immunogenic potential of the tumor microenvironment (TME) and the likelihood of response to immunotherapy. The emerging literature has identified key immune cell populations that significantly impact immune activation or suppression within the TME. This study investigated candidate T-cell populations and their differential infiltration within different tumor types as estimated from mRNA co-expression levels of the corresponding cellular markers.
View Article and Find Full Text PDFSci Rep
December 2024
Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Charité - Universitätsmedizin Berlin, Geschäftsführung, Charitéplatz 1, 10117, Berlin, Germany.
Quantitative magnetic resonance imaging (qMRI) involves mapping microstructure in standardized units sensitive to histological properties and supplements conventional MRI, which relies on contrast weighted images where intensities have no biophysical meaning. While measuring tissue properties such as myelin, iron or water content is desired in a disease context, qMRI changes may typically reflect mixed influences from aging or pre-clinical degeneration. We used a fast multi-parameter mapping (MPM) protocol for clinical routine at 3T to reconstruct whole-brain quantitative maps of magnetization transfer saturation (MT), proton density (PD), longitudinal (R1), and transverse relaxation rate (R2*) with 1.
View Article and Find Full Text PDFChest
December 2024
Amsterdam University Medical Centres, Amsterdam, the Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; University of Leuven, the Department of Microbiology Immunology & Transplantation, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. Electronic address:
Asthma is a common multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of targeted biologic treatment options, the disease remains uncontrolled in a substantial proportion of patients with risk of exacerbations, requiring systemic corticosteroids, and with progressive disease. Current international guidelines advocate a personalized management approach to patients with uncontrolled severe asthma.
View Article and Find Full Text PDFGenet Med Open
September 2024
Department of Pediatrics, Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH.
J Neurol
December 2024
Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy.
In this observational cross-sectional study conducted in Italy, sociodemographic and disease data were collected from a multiple sclerosis (MS) population treated with disease-modifying therapies (DMTs). A prevalence-based cost-of-illness analysis was subsequently carried out. In total, 393 MS patients were enrolled, 65.
View Article and Find Full Text PDF